PVmed Showcases Dual-Line AI Products in Radiology and Radiotherapy at CCR 2018 & CSTRO 2018
From November 7 to 10, 2018, the Chinese Congress of Radiology (CCR 2018) was grandly held at the China National Convention Center in Beijing. Concurrently, the 15th National Academic Conference on Radiation Oncology of the Chinese Medical Association (CSTRO 2018) took place at the Hangzhou International Expo Center. As a leader in medical artificial intelligence and algorithm technologies, Baishi showcased its suite of AI products at these premier annual conferences in the fields of radiology and radiation oncology.
Baishi Medical holds international leading positions in multiple technologies within the field of artificial intelligence for medical imaging. At this conference, Baishi showcased a range of radiology products and engaged in in-depth exchanges with industry experts and scholars.
As Bosh Vision’s medical imaging AI technology matures and its deep learning datasets become increasingly refined, the company’s radiology products—including bone suppression for DR chest X-rays, DR-based tuberculosis detection, and pulmonary nodule detection on chest CT scans—are also reaching greater maturity.
The team members at Baishi Medical bring over a decade of experience in both the healthcare and artificial intelligence industries. As a result, despite the company’s relatively short history, its product quality rivals that of industry giants in the fields of radiology and radiation therapy.
On November 8, the 5th National Congress of the Radiation Oncology Branch of the Chinese Medical Association officially opened at the Hangzhou International Expo Center, marking the second day of CCR 2108. Baishi Medical also participated in this significant conference in the field of radiation therapy.
During the conference, Baishi Medical’s automated delineation system for radiotherapy target volumes in nasopharyngeal carcinoma attracted significant attention. Target volume delineation, particularly when leveraging artificial intelligence, presents a high level of technical difficulty. Nasopharyngeal carcinoma exhibits distinct regional characteristics, with a higher prevalence in southern China, and available case data are currently quite limited. Developing an automated delineation system for radiotherapy target volumes under such challenging conditions—marked by both substantial technical complexity and extremely scarce data—is exceptionally difficult. Consequently, this product has garnered widespread attention from physicians and industry peers since its launch.
At the 2nd International Symposium on Image Computing and Digital Medicine (ISICDM 2018) held in Chengdu, Professor Lu Yao, Chairman of Bosh Medical, delivered a keynote address as an invited guest on intelligent radiotherapy and target volume delineation, during which he showcased Bosh’s product in the field of radiotherapy: the automatic target delineation system for nasopharyngeal carcinoma.
Baishi has always adhered to its corporate mission: to address clinical needs by better assisting physicians and serving patients, rather than limiting itself to currently trending sectors. It advances wherever there is clinical demand. Therefore, Baishi’s products are not only focused on radiology but also extend to the more challenging field of radiation therapy. Notably, in actual clinical trials, Baishi’s products have achieved top-tier performance within the industry.
Chairman of Baishi Medical: Lu Yao
2017 was a year of rapid development for medical artificial intelligence, with the industry landscape undergoing dynamic changes. During this period, Bosh Vision Medical achieved significant growth, securing tens of millions in financing and progressively strengthening its team composed of professionals with expertise in both the healthcare industry and artificial intelligence technology.
In 2018, from the CSTRO conference in Hangzhou, a key event in the field of radiation oncology, to the CCR annual meeting in Beijing, a premier gathering in the radiology sector, Baishi demonstrated top-tier industry standards in both artificial intelligence technology and professional expertise in radiation oncology. We have every reason to believe that this is not their final destination, as they have been consistently moving forward without pause.